1. Home
  2. REVB vs GV Comparison

REVB vs GV Comparison

Compare REVB & GV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • GV
  • Stock Information
  • Founded
  • REVB 2020
  • GV 2013
  • Country
  • REVB United States
  • GV Canada
  • Employees
  • REVB N/A
  • GV N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • GV Other Consumer Services
  • Sector
  • REVB Health Care
  • GV Real Estate
  • Exchange
  • REVB Nasdaq
  • GV Nasdaq
  • Market Cap
  • REVB 5.4M
  • GV 5.8M
  • IPO Year
  • REVB N/A
  • GV 2022
  • Fundamental
  • Price
  • REVB $0.40
  • GV $2.25
  • Analyst Decision
  • REVB
  • GV
  • Analyst Count
  • REVB 0
  • GV 0
  • Target Price
  • REVB N/A
  • GV N/A
  • AVG Volume (30 Days)
  • REVB 6.8M
  • GV 309.4K
  • Earning Date
  • REVB 11-08-2024
  • GV 01-28-2025
  • Dividend Yield
  • REVB N/A
  • GV N/A
  • EPS Growth
  • REVB N/A
  • GV N/A
  • EPS
  • REVB N/A
  • GV 0.32
  • Revenue
  • REVB N/A
  • GV $9,380,985.00
  • Revenue This Year
  • REVB N/A
  • GV N/A
  • Revenue Next Year
  • REVB N/A
  • GV N/A
  • P/E Ratio
  • REVB N/A
  • GV $7.10
  • Revenue Growth
  • REVB N/A
  • GV 11.25
  • 52 Week Low
  • REVB $0.28
  • GV $1.00
  • 52 Week High
  • REVB $25.26
  • GV $8.85
  • Technical
  • Relative Strength Index (RSI)
  • REVB 39.87
  • GV 58.05
  • Support Level
  • REVB $0.39
  • GV $2.11
  • Resistance Level
  • REVB $0.53
  • GV $2.71
  • Average True Range (ATR)
  • REVB 0.13
  • GV 0.25
  • MACD
  • REVB 0.00
  • GV -0.01
  • Stochastic Oscillator
  • REVB 7.54
  • GV 54.46

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About GV Visionary Education Technology Holdings Group Inc.

Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.

Share on Social Networks: